Editorial commentary: meeting a paramount challenge

Ping Yang

Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA

Correspondence to: Ping Yang. Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA. Email: Yang.Ping@mayo.edu.

Provenance: This is an invited Editorial commissioned by Section Editor Dawei Yang (Zhongshan Hospital, Fudan University, Shanghai Respiratory Research Institution, Chinese Alliance Against Lung Cancer, Shanghai, China).


Submitted Mar 07, 2018. Accepted for publication Mar 09, 2018.
doi: 10.21037/tlcr.2018.03.17
View this article at: http://dx.doi.org/10.21037/tlcr.2018.03.17

As predicted by the Global Burden of Disease study 2020 (1), lung cancer will continue to be the heaviest burden worldwide to the public health among all malignant diseases (2). With tobacco consumption shifted from the rich to the poor in the recent decade, 50% of smokers are residing in 5 counties, i.e., China, Brazil, Russia, India and Indonesia, underlining where most of the high-risk populations will be to acquire lung cancer (3). Due to the obnoxiously late stage at the time of diagnosis, 5-year survival rate of lung cancer patients remains to be under 20% even in economically advanced countries (4), which signifies the crucial importance of screening and early detection in high risk populations. However, defining and focusing on the at-risk individuals are far from adequate and feasible. For examples, the foremost pitfalls of the currently and publically implemented screening criteria in the United States using low dose CT scan (5) could only identify 30-40% lung cancer in the population, yet accompanying a greater than 90% false positivity. Moreover, substantially high risk individuals were missed by the current definition (6,7). Therefore, a paramount challenge is to establish precision screening scheme with nearly perfect early detection tools.

This multicenter investigation, led by Dr. C Bai with co-leading authors Drs. D Yang and X Zhang, enrolled 715 participants from 5 regional centers in Beijing, Zhengzhou, Nanjing, Shanghai and Chongqing, analyzed four serum biomarkers (ProGRP, CEA, SCC, and CYFRA21-1) along with relevant clinical information, and developed two prediction models: one for patient risk and one for lung nodule risk (8). Both models demonstrated excellent discrimination for the early diagnosis of lung cancer, with the under the receiver operating characteristic (ROC) curve (AUC) of patient risk model at 0.72, and of the nodule risk model at 0.92 relative to American College of Chest Physicians (ACCP) model (9). The authors compared with and surpassed the Mayo Clinic model suggested by ACCP guidelines (0.92 vs. 0.84) (8), which is consistent with other previously reported studies (Table 1) (10-12). Two key messages could be drawn from the LCPB study based on interpretations of the results: first, to the researchers, the improved power of discrimination illustrated the foreseeing capability to stratify patients with different levels of lung cancer risk although the sensitivity and specificity are not ideal at all settings considered. Second, to the persons at high risk of lung cancer and the care providers, these new models hold high potential to be applicable in high-risk populations upon further evaluation of additional biological markers.
Table 1 Comparative models in discrimination for early diagnosis of lung cancer

<table>
<thead>
<tr>
<th>Model name</th>
<th>Sample size</th>
<th>Population/country</th>
<th>Relative ROC-AUC</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nodule risk</td>
<td>342</td>
<td>Chinese</td>
<td>0.84*</td>
<td>(8)</td>
</tr>
<tr>
<td>BIMC</td>
<td>200</td>
<td>Italy</td>
<td>0.64*/0.88**</td>
<td>(10)</td>
</tr>
<tr>
<td></td>
<td>285</td>
<td></td>
<td>0.78*/0.90**</td>
<td>(11)</td>
</tr>
<tr>
<td>POM</td>
<td>241</td>
<td>Japan</td>
<td>0.67*</td>
<td>(12)</td>
</tr>
</tbody>
</table>

*, the ROC curve (AUC) using ACCP guidelines (9); **, the ROC curve (AUC) using BIMC (13). ROC, receiver operating characteristic; BIMC, Bayesian Inference Malignancy Calculator; POM, probability of malignancy.

Acknowledgements

None.

Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

References


Cite this article as: Yang P. Editorial commentary: meeting a paramount challenge. Transl Lung Cancer Res 2018;7(Suppl 2):S158-S159. doi: 10.21037/tlcr.2018.03.17